Page last updated: 2024-12-05

quassin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Quassin is a bitter-tasting tetranortriterpenoid. It is a natural product that was first isolated from the wood of the quassia tree (Quassia amara). Quassin has a variety of biological activities, including anti-inflammatory, antimalarial, and anticancer effects. It is thought to work by inhibiting protein synthesis. Quassin has been studied for its potential use in the treatment of a variety of diseases, including cancer, malaria, and inflammation. It has also been used as a pesticide and a bitter agent in food. Quassin is synthesized via a complex biosynthetic pathway that involves several steps, including the cyclization of a diterpene precursor. '

quassin: article discusses quassinoid principle; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65571
CHEMBL ID517016
CHEBI ID8692
SCHEMBL ID140454
MeSH IDM0055714
PubMed CID4998
MeSH IDM0055714

Synonyms (42)

Synonym
NSC36342 ,
nsc-36342
dimethoxy(tetramethyl)[?]trione
quassine
(3as,6ar,7as,8s,11as,11bs,11cs)-1,3a,4,5,6a,7,7a,8,11,11a,11b,11c-dodecahydro-2,10-dimethoxy-3,8,11a,11c-tetramethyldibenzo(de,g)chromene-1,5,11-trione
C08778
quassin
76-78-8
LMPR0106110002
chebi:8692 ,
CHEMBL517016
2,12-dimethoxypicrasa-2,12-diene-1,11,16-trione
einecs 200-985-9
nsc 36342
unii-qp1yak6qgk
qp1yak6qgk ,
CCG-208319
SCHEMBL140454
quassin [mi]
quassin [inci]
sr-05000002312
SR-05000002312-3
SR-05000002312-2
(1s,2s,6s,7s,9r,13r,17s)-4,15-dimethoxy-2,6,14,17-tetramethyl-10-oxatetracyclo[7.7.1.02,7.013,17]heptadeca-4,14-diene-3,11,16-trione
AKOS032948714
HY-N1581
1,1-dimethylpropylhydroperoxide
Q2079986
CS-0017129
MS-26447
DTXSID30878613
E88800
mls002607964 ,
picrasa-2,12-diene-1,11,16-trione, 2,12-dimethoxy-
nigakilactone d
smr001526722
FT-0603283
2,12-dimethoxypicrasa-2,12-diene-1,11,16-trione #
IOSXSVZRTUWBHC-UHFFFAOYSA-N
4,15-dimethoxy-2,6,14,17-tetramethyl-10-oxatetracyclo[7.7.1.02,7.013,17]heptadeca-4,14-diene-3,11,16-trione
2,10-dimethoxy-3,3a1,8,11a-tetramethyl-3a,4,6a,7,7a,8-hexahydrodibenzo[de,g]chromene-1,5,11(3a1h,11ah,11bh)-trione
DTXSID30861626

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" At oral doses up to 1000 mg/kg using rats, Quassin was not toxic in acute and short-term tests, but some reversible piloerection, decrease in motor activity, and a partial loss of righting reflex were found in mice at 500 mg/kg."( Final report of the safety assessment of Alcohol Denat., including SD Alcohol 3-A, SD Alcohol 30, SD Alcohol 39, SD Alcohol 39-B, SD Alcohol 39-C, SD Alcohol 40, SD Alcohol 40-B, and SD Alcohol 40-C, and the denaturants, Quassin, Brucine Sulfate/Brucine,
, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID422117Inhibition of protein synthesis in cell-free extract of mouse Krebs2 cells by SDS-PAGE2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID422103Inhibition of TPA-induced NF-kappaB transfected in HEK293 cells at 0.1 to 10 uM treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID1639473Inhibition of H2O2-induced apoptosis in human SH-SY5Y cells assessed as viable cells at 25 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 4 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 50.2019Journal of natural products, 04-26, Volume: 82, Issue:4
Quassinoids from Picrasma quassioides and Their Neuroprotective Effects.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID356618Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum K12003Journal of natural products, Nov, Volume: 66, Issue:11
Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone.
AID1639474Inhibition of H2O2-induced apoptosis in human SH-SY5Y cells assessed as early apoptotic cells at 25 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 4 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (2019Journal of natural products, 04-26, Volume: 82, Issue:4
Quassinoids from Picrasma quassioides and Their Neuroprotective Effects.
AID1639471Neuroprotective activity against H2O2-induced cytotoxicity in human SH-SY5Y cells at 25 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 4 hrs by MTT assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
Quassinoids from Picrasma quassioides and Their Neuroprotective Effects.
AID422104Inhibition of TPA-induced SRE transfected in HEK293 cells at 0.1 to 10 uM treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID1639475Inhibition of H2O2-induced apoptosis in human SH-SY5Y cells assessed as late apoptotic cells at 25 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 4 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (R2019Journal of natural products, 04-26, Volume: 82, Issue:4
Quassinoids from Picrasma quassioides and Their Neuroprotective Effects.
AID422102Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity at 0.1 to 10 uM treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID422099Inhibition of TPA-induced AP1 transfected in HEK293 cells assessed as inhibition of beta-lactamase reporter activity treated 1 hr before TPA stimulation measured after 18 hrs by luciferase reporter gene assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID356617Cytotoxicity against human KB cells by microplate method2003Journal of natural products, Nov, Volume: 66, Issue:11
Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone.
AID1639476Inhibition of H2O2-induced apoptosis in human SH-SY5Y cells assessed as necrotic cells at 25 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 4 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 22019Journal of natural products, 04-26, Volume: 82, Issue:4
Quassinoids from Picrasma quassioides and Their Neuroprotective Effects.
AID356616Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected erythrocytes by [3H]hypoxanthine uptake2003Journal of natural products, Nov, Volume: 66, Issue:11
Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone.
AID422119Growth inhibition of human NCI60 cells2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID422118Inhibition of protein synthesis in human HeLa cells assessed as [35S]methionine incorporation into protein treated for 45 mins before [35S]methionine addition by Whatman paper analysis2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Quassinoid inhibition of AP-1 function does not correlate with cytotoxicity or protein synthesis inhibition.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (22.22)18.7374
1990's6 (16.67)18.2507
2000's8 (22.22)29.6817
2010's11 (30.56)24.3611
2020's3 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.29 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index59.52 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews4 (12.90%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other27 (87.10%)84.16%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]